Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 344

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome–positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study

Open access
de Labarthe, Adrienne, Rousselot, Philippe, Huguet-Rigal, Françoise, Delabesse, Eric, Witz, Francis, Maury, Sébastien, Réa, Delphine, Cayuela, Jean-Michel, Vekemans, Marie-Christine, Reman, Oumedaly, Buzyn, Agnès, Pigneux, Arnaud, Escoffre, Martine, Chalandon, Yves, MacIntyre, Elizabeth, Lhéritier, Véronique, Vernant, Jean-Paul, Thomas, Xavier, Ifrah, Norbert, Dombret, Hervé, for the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)·2007·Blood

Abstract

The combination of imatinib with chemotherapy has been recently reported as very promising in patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). During 2004 and 2005, 45 patients with newly diagnosed Ph+ ALL were treated in the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAAPH) 2003 study, in which imatinib was started with HAM (mitoxantrone with intermediate-dose cytarabine) consolidation in good early responders (corticosensitive and chemosensitive ALL) or earlier during the induction course in combination with dexamethasone and vincristine in poor early responders (corticoresistant and/or chemoresistant ALL). Imatinib was then continuously administered until stem cell transplantation (SCT). Overall, complete remission (CR) and BCR-ABL real-time quantitative polymerase chain reaction (RQ-PCR) negativity rates were 96% and 29%, respectively. All of the 22 CR patients (100%) with a donor actually received allogeneic SCT in first CR. At 18 months, the estimated cumulative incidence of relapse, disease-free survival, and overall survival were 30%, 51%, and 65%, respectively. These 3 end points compared very favorably with results obtained in the pre-imatinib LALA-94 trial. This study confirms the value of the combined approach and encourages prospective trials to define the optimal chemotherapy that has to be combined with imatinib and to carefully reevaluate the place of allogeneic SCT in this new context.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2006-03-011908

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 344

Metadata

Authors
de Labarthe, A., Rousselot, P., Huguet-Rigal, F., Delabesse, E., Witz, F., Maury, S., Réa, D., Cayuela, J.-M., Vekemans, M.-C., Reman, O., Buzyn, A., Pigneux, A., Escoffre, M., Chalandon, Y., MacIntyre, E., Lhéritier, V., Vernant, J.-P., Thomas, X., Ifrah, N., Dombret, H., & for the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)
Venue
Blood
Published
2006-10-24
Volume
109
Issue
4
Pages
1408-1413
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2000116184
Cited by
344
References
9
FWCI
26.72
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome–positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. https://app.cochat.ai/papers/10.1182/blood-2006-03-011908
The paper
de Labarthe, A., Rousselot, P., Huguet-Rigal, F., Delabesse, E., Witz, F., Maury, S., Réa, D., Cayuela, J.-M., Vekemans, M.-C., Reman, O., Buzyn, A., Pigneux, A., Escoffre, M., Chalandon, Y., MacIntyre, E., Lhéritier, V., Vernant, J.-P., Thomas, X., Ifrah, N., . . . for the Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). (2007). Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome–positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood. https://doi.org/10.1182/blood-2006-03-011908

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.